financetom
Business
financetom
/
Business
/
Sustainable aviation fuel costs must be lower, Exxon VP says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sustainable aviation fuel costs must be lower, Exxon VP says
Mar 22, 2024 8:19 PM

CHICAGO, March 22 (Reuters) - Costs are the main

obstacle to increasing the use of sustainable aviation fuel

(SAF), Exxon Mobil ( XOM ) Senior Vice President Jack Williams

said on Friday.

SAF accounts for just 0.2% of the jet fuel market but

policymakers including U.S. President Joe Biden see its adoption

as a way to meet goals on lowering carbon emissions.

But SAF, a biofuel made from plant or animal materials

including used cooking oil or agricultural waste, is up to five

times more expensive than regular fuel.

"There's one big negative and that's the cost," Williams

said at a conference near Chicago. "As we think about how we

want to grow SAF ... we have got to focus on how do we minimize

the costs?"

Williams said demand for jet fuel could increase from 7

million barrels a day now to 12 million barrels a day in 2050.

Seven million barrels a day is the same as the International

Energy Agency's estimate for all jet fuel demand. By comparison,

current production of SAF is only 15.8 million gallons per year,

as per U.S. government data.

Williams described the Biden administration's Inflation

Reduction Act as the catalyzing action for biofuel production as

well as carbon capture and storage and low carbon hydrogen.

Biden launched a challenge in 2021 to supply at least 3

billion gallons of SAF annually by 2030.

Major airlines, including Delta Air Lines ( DAL ) and

Southwest Airlines ( LUV ), have said they want to replace 10%

of jet fuel with SAF by 2030.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation
Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation
May 25, 2025
11:41 AM EDT, 04/28/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said Monday its license partner, argenx, received a positive opinion for VYVGART from the European Medicines Agency's Committee for Medicinal Products for Human Use to treat adults with chronic inflammatory demyelinating polyneuropathy. The subcutaneous injection of VYVGART is co-formulated with Halozyme's ENHANZE drug delivery technology. CIDP is a...
Zentalis Pharmaceuticals Doses 1st Patient in Part 2 of Ovarian Cancer Clinical Trial
Zentalis Pharmaceuticals Doses 1st Patient in Part 2 of Ovarian Cancer Clinical Trial
May 25, 2025
11:41 AM EDT, 04/28/2025 (MT Newswires) -- Zentalis Pharmaceuticals ( ZNTL ) said Monday it has dosed the first patient in part 2 of the phase 2 clinical trial of azenosertib in ovarian cancer patients. The company said it expects to release topline data from part 2 by the end of 2026, adding that a successful trial can support an...
Update: Osisko Development Provides Optimized Feasibility Study Results for Cariboo Gold Project
Update: Osisko Development Provides Optimized Feasibility Study Results for Cariboo Gold Project
May 25, 2025
11:44 AM EDT, 04/28/2025 (MT Newswires) -- (Adds comment and updates shares.) Osisko Development ( ODV ) reported Monday the results of an optimized feasibility study for the Cariboo gold project in British Columbia. The company said the study supports the development of an $881-million mining project producing 190,000 ounces of gold annually over a 10-year mine life The study...
Guardant Health Launches Molecular Profiling Cancer Test
Guardant Health Launches Molecular Profiling Cancer Test
May 25, 2025
11:45 AM EDT, 04/28/2025 (MT Newswires) -- Guardant Health ( GH ) said Monday it launched its its molecular profiling test Guardant360 Tissue, which provides a more complete view of cancer. The tumor tissue test incorporates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data, the company said. The test is covered by Medicare for eligible patients,...
Copyright 2023-2025 - www.financetom.com All Rights Reserved